TRAW
Traws Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.55
+1.49%Year over year
Reported trailing growth
- Revenue
- +606.3%
- EBITDA
- +34.0%
- EBIT
- +34.7%
- EPS
- +76.4%
- Free cash flow
- +32.2%
- Operating cash flow
- +32.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +85.6%
Three-year CAGR
- Revenue
- +131.1%
- EBITDA
- +89.3%
- EBIT
- +63.8%
- Net income
- +116.8%
- EPS
- +102.4%
- Free cash flow
- +30.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026